Biomedical Engineering Reference
In-Depth Information
18. Weinstein MC , O ' Brien B , Hornberger J , Jackson J , Johannesson M , McCabe C.
Principles of good practice for decision analytic modeling in health-care evaluation:
Report of the ISPOR Task Force on Good Research Practices—Modeling studies.
Value Health
2003 ; 6 : 9 - 17 .
19. Arnold RJ , Ekins S . Time for cooperation in health economics among the modelling
community .
PharmacoEconomics
2010 ; 28 : 609 - 613 .
20. Vandenbroucke JP , Psaty BM . Benefi ts and risks of drug treatments: How to
combine the best evidence on benefi ts with the best data about adverse effects.
JAMA
2008 ; 300 : 2417 - 2419 .
21. NIH . Clinical Research Policy Analysis and Coordination . Available: http://crpac.
od.nih.gov/issue_adverse.asp .
22. Papanikolaou PN , Ioannidis JP . Availability of large - scale evidence on specifi c
harms from systematic reviews of randomized trials.
Am J Med
2004 ; 117 : 582 - 589 .
23. Scharf O , Colevas AD . Adverse event reporting in publications compared with
sponsor database for cancer clinical trials.
J Clin Oncol
2006 ; 24 : 3933 - 3938 .
24. (CBER) USDoHaHSFaDACfDEaRCaCfBEaR. Guidance for industry, develop-
ment and use of risk minimization action plans. Available: http://www.fda.gov/cder/
guidance/index.htm.
25. (CBER) USDoHaHSFaDACfDEaRCaCfBEaR. Guidance for industry, good
pharmacovigilance practices and pharmacoepidemiologic assessment. Available:
http://www.fda.gov/cder/guidance/index.htm .
26. (CBER) USDoHaHSFaDACfDEaRCaCfBEaR. Guidance for industry, premar-
keting risk assessment. Available: http://www.fda.gov/cder/guidance/index.htm.
27. Fleming TR. Identifying and addressing safety signals in clinical trials .
N Engl J
Med
2008 ; 359 : 1400 - 1402 .
28. Avorn J. Drug warnings that can cause fi ts—Communicating risks in a data-poor
environment.
N Engl J Med
2008 ; 359 : 991 - 994 .
29. Williams DP , Park BK . Idiosyncratic toxicity: The role of toxicophores and bioac-
tivation .
Drug Discov Today
2003 ; 8 : 1044 - 1050 .
30. Uetrecht J. Screening for the potential of a drug candidate to cause idiosyncratic
drug reactions.
Drug Discov Today
2003 ; 8 : 832 - 837 .
31. Li AP . A review of the common properties of drugs with idiosyncratic hepatotoxic-
ity and the “multiple determinant hypothesis” for the manifestation of idiosyncratic
drug toxicity.
Chem Biol Interact
2002 ; 142 : 7 - 23 .
32. Kaplowitz N. Idiosyncratic drug hepatotoxicity .
Nat Rev Drug Discov
2005 ; 4 :
489 - 499 .
33. Lee WM . Drug - induced hepatotoxicity .
N Engl J Med
2003 ; 349 : 474 - 485 .
34. Ito K , Chiba K , Horikawa M , Ishigami M , Mizuno N , Aoki J . Which concentration
of the inhibitor should be used to predict in vivo drug interactions from in vitro
data?
AAPS PharmSci
2002 ; 4 : E25 .
35. Boelsterli UA , Ho HK , Zhou S , Leow KY . Bioactivation and hepatotoxicity of
nitroaromatic drugs.
Curr Drug Metab
2006 ; 7 : 715 - 727 .
36. Kassahun K , Pearson PG , Tang W , McIntosh I , Leung K , Elmore C . Studies on the
metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence
for novel biotransformation pathways involving quinone methide formation and
thiazolidinedione ring scission.
Chem Res Toxicol
2001 ; 14 : 62 - 70 .
Search WWH ::
Custom Search